致：香港交易及結算所有限公司 公司名稱: Cloudbreak Pharma Inc. 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02592 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | 本月底法定/註冊股本總額： USD 200,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的 ...

Core Viewpoint - The company, 拨康视云-B (02592), announced the issuance of approximately 3.888 million shares under a Series C equity incentive plan on October 30, 2025 [1] Group 1 - The share issuance is part of a broader equity incentive arrangement aimed at motivating and retaining key personnel within the company [1] - The total number of shares being issued is approximately 3.888 million [1]

Core Viewpoint - The company, Bolekang Shiyun-B (02592), announced the issuance of approximately 3.888 million shares under its Series C equity incentive plan, scheduled for October 30, 2025 [1] Group 1 - The company is set to issue around 3.888 million shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： Cloudbreak Pharma Inc. 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02592 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

Core Insights - The current state of the biopharmaceutical market shows a stark contrast between the primary and secondary markets, a situation not seen in the past five years [1] - Since 2022, the investment enthusiasm in the biopharmaceutical sector has declined, leading to challenges such as reduced R&D efficiency and insufficient commercialization [1][3] - Key areas for new development in the biopharmaceutical industry include overseas licensing, AI healthcare, and improved payment systems [1][7] Market Dynamics - The primary market is primarily funded by state-owned capital, while market-driven funds have not yet returned [2][3] - The Hong Kong stock market is becoming a significant option for biopharmaceutical companies to go public, although there is a notable disparity in market performance [2][3] - The secondary market, particularly in Hong Kong, has seen continuous growth, driven by innovative drug companies reaching the delivery stage [3] Investment Trends - The investment landscape has shifted, with a focus on companies that can demonstrate strong overseas licensing capabilities as a measure of competitiveness [7][8] - The amount of overseas licensing for domestic innovative drugs reached $25.7 billion in 2023, surpassing the amount for technology introduced from abroad [7] - By 2025, the overseas licensing amount is expected to exceed $100 billion, indicating a significant trend towards global market engagement [7] Entrepreneurial Guidance - Entrepreneurs are advised to fully commit to their ventures and develop comprehensive strategic plans to navigate the current market environment [5][6] - Effective communication between entrepreneurs and investors is crucial for capitalizing on growth opportunities [5][6] - Companies should avoid the pressure of rapid expansion and instead focus on aligning their development pace with market demands and financial conditions [6] Future Outlook - The biopharmaceutical industry is expected to benefit from policy improvements and technological advancements, creating new growth opportunities [7][8] - The ability to adapt to external policy risks, particularly in overseas markets, will be essential for companies looking to expand internationally [8] - The long-term investment horizon in the biopharmaceutical sector remains promising, despite the current challenges [8]

Core Viewpoint - The company announced a grant of restricted share units under its post-IPO equity incentive plan, which requires acceptance from the grantees to become effective [1] Group 1 - The company will grant 5 million restricted share units to Whitcup Life Sciences LLC, a service provider involved in R&D and business development services [1] - The grant to Whitcup Life Sciences LLC represents more than 0.1% of the company's total issued shares as of the grant date [1] - Whitcup Life Sciences LLC is wholly owned by Dr. Scott Whitcup, who serves as the chairman of the company's scientific advisory committee [1]

Core Viewpoint - The company announced a grant of 5 million restricted stock units to Whitcup Life Sciences LLC as part of its post-IPO equity incentive plan, effective October 22, 2025 [1] Group 1 - The board of directors approved the issuance of 5 million restricted stock units [1] - The grant is equivalent to 5 million shares of the company's stock [1]

Core Viewpoint - The company announced a grant of 5 million restricted stock units to service provider Whitcup Life Sciences LLC as part of its post-IPO equity incentive plan, effective October 22, 2025 [1] Group 1 - The board of directors approved the issuance of 5 million restricted stock units [1] - The granted units correspond to 5 million shares of the company's stock [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 根據首次公開發售後股權激勵計劃授出受限制股份單位 根據首次公開發售後股權激勵計劃授出受限制股份單位 本公告乃由本公司根據上市規則第17.06A條、17.06B條及17.06C條作出。茲提述本公司日期為2025 年6月24日的招股章程，內容有關（其中包括）首次公開發售後股權激勵計劃。 行使 ： 受限制股份單位在未歸屬前不得行使。根據計劃規則及相關授出函 件的條款，是項授出項下的受限制股份單位一經歸屬將自動行使。 股份於授出日期的收市價 ： 每股股份4.74港元 董事會議決根據首次公開發售後股權激勵計劃的條款向承授人授出首次公開發售後股權激勵計劃項 下的受限制股份單位獎勵，惟須獲承授人接納，方可作實。 所授出受限制股份單位獎勵的詳情 建議買入價 ： 每股股份0.0001美元，即相 ...

Core Points - The company, 拨康视云-B (02592), announced the issuance of 1.785 million shares on October 3, 2025, as part of its 2023 equity incentive plan [1] Group 1 - The share issuance is part of a broader strategy to incentivize employees and align their interests with those of shareholders [1]